WO2005084640A1 - Stable pharmaceutical solution formulations for pressurized metered dose inhalers - Google Patents
Stable pharmaceutical solution formulations for pressurized metered dose inhalers Download PDFInfo
- Publication number
- WO2005084640A1 WO2005084640A1 PCT/EP2005/002042 EP2005002042W WO2005084640A1 WO 2005084640 A1 WO2005084640 A1 WO 2005084640A1 EP 2005002042 W EP2005002042 W EP 2005002042W WO 2005084640 A1 WO2005084640 A1 WO 2005084640A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- hydroxy
- phosphoric acid
- present
- metered dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0222—Materials for reducing friction
Definitions
- the present invention relates to stable pharmaceutical solution formulations to be used with pressurized metered dose inhalers (MDIs) suitable for aerosol administration.
- MDIs pressurized metered dose inhalers
- the present invention relates to solutions to be used with pressurized metered dose inhalers (MDIs), which are suitable for aerosol administration containing the ⁇ 2 -agonist 8- hydroxy-5-[(l R)- 1 -hydroxy-2-[[(l R)-2-(4-methoxyphenyl)- 1 -methylethyl] amino] ethyl]- 2(lH)-quinolinone or a salt thereof (the hydrochloride salt is hereinafter referred to as TA 2005) and which is stable at room temperature for a pharmaceutically acceptable shelf-life.
- MDIs pressurized metered dose inhalers
- DISCUSSION OF THE BACKGROUND Pressurized metered dose inhalers are well known devices for administering pharmaceutical products to the respiratory tract by inhalation.
- Drugs commonly delivered by inhalation include bronchodilators such as ⁇ -agonists and anticholinergics, corticosteroids, anti-leukotrienes, anti-allergies and other materials that may be efficiently administered by inhalation, thus increasing the therapeutic efficacy and reducing side effects.
- MDIs use a propellant to expel droplets containing the pharmaceutical product to the respiratory tract as an aerosol.
- Formulations for aerosol administration via MDIs can be solutions or suspensions.
- Solution formulations offer the advantage of being homogeneous with the active ingredient and excipients completely dissolved in the propellant vehicle or its mixture with suitable co-solvents such as ethanol. Solution formulations also obviate physical stability problems associated with suspension formulations so assuring more consistent uniform dosage administration.
- the preferred propellants used in aerosols for pharmaceutical use have been a group of chlorofluorocarbons which are commonly called Freons or CFCs, such as CC1 3 F (Freon 11 or CFC-11), CC1 2 F 2 (Freon 12 or CFC-12), and CC1F 2 -CC1F 2 CFreon 114 or
- HFAs Hydrofluoroalkanes
- HFAs and in particular 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3- heptafluoropropane (HFA 227) have been acknowledged to be the best candidates for non- CFC propellants and a number of medicinal aerosol formulations using such HFA propellant systems have been disclosed. Due to the higher polarity of the HFA propellants, in particular of HFA 134a
- HFA solution formulations may suffer to a greater extent of chemical stability problems with respect to the corresponding CFC formulations.
- Preparation of stable HFA solution formulations is even more critical when bronchodilator ⁇ 2 -agonists belonging to the class of the phenylalkylamino derivatives are concerned; in particular, 8-hydroxy-5-[(lR)-l-hydroxy-2-[[(lR)-2-(4-methoxyphenyl)-l- methylethyl] amino]ethyl]-2(lH)-quinolinone suffers from chemical stability problems in this kind of vehicle and it is highly susceptible to chemical degradation.
- pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD)
- a pharmaceutical composition comprising as active ingredient 8-hydroxy-5-[(lR)-l-hydroxy-2-[[(lR)-2-(4- methoxyphenyl)-l-memyle1i ⁇ yl]--mino]ethyl]-2(lH)-quinol__none or a salt thereof, in particular the hydrochloride salt, in a solution of a liqu&fied HFA propellant, a co-solvent selected from pharmaceutically acceptable alcohols and a specific amount of high concentrated (i.e. more than about 10 M, preferably more than about 12 M and in particular about 15 M) phosphoric acid.
- high concentrated i.e. more than about 10 M, preferably more than about 12 M and in particular about 15 M
- the apparent pH of said solution is comprised between 2.5 and 5.5.
- the formulation is preferably a solution in which "the active ingredient is completely dissolved.
- the composition of the invention may be contained in a pressurized MDI having part or all of its internal metallic surfaces made of stainless ste&l, anodised aluminum or lined with an inert organic coating.
- the stabilizing effect of phosphoric acid is not strictly correlated with its w/w percent amount in the formulation and when about 15 M phosphoric acid is used, it is present in a concentration interval from 0.0004 to 0.040 % by weight on the total weight of the formulation, being O.0008 w/w to 0.0075% w/w the preferred concentration interval.
- the corresponding apparent pH interval is of .2.5-5.5, preferably 3.0-5.5, more preferably 3.5-5.0.
- the attribution 'apparent' is used as pH is indeed characteristic of aqueous liquids where water is the dominant component (Mole Fraction > 0.95).
- HFA propellant and a cosolvent not only depends on the acidity function of the solution, but it is also catalyzed by trace levels of metal ions and that TA 2005 stability can be enhanced by adding to the solution specific amounts of high concentrated phosphoric acid both to adjust the apparent pH in a well defined interval and to sequester metal ions.
- inert containers in particular having part or all of their internal metallic surfaces lined with an inert organic coating can enhance the chemical stability of the active ingredient in the HFA propellant solution.
- a pressurised MDI for administering pharmaceutical doses consisting of a container lined with an inert coating, filled with a pharmaceutical composition
- a pharmaceutical composition comprising a solution of 8-hydroxy-5- [(lR)-l-hydroxy-2-[[(lR)-2-(4-methoxyphenyl)-l-methylethyl]amino]ethyl]-2(lH)- quinolinone in HFA 134a as a propellant in turn containing from about 8 to about 15% w/w ethanol as a co-solvent, further containing from 0.0004% w/w to 0.0075% w/w of 85% (15.2 M) phosphoric acid.
- the apparent pH of said solution is comprised between 3.0 and 5.5.
- the expression '% w/w' means the weight percentage of the component with respect to the total weight of the composition.
- the active ingredient in such a composition filled in said container has a good chemical stability and shelf-life at room temperature and meets the requirements of the ICH
- the pharmaceutical formulations of the invention may further contain further excipients and in particular a low volatility component in order to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler.
- MMAD mass median aerodynamic diameter
- the applicant described solution compositions for use in an aerosol inhaler comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler.
- HFA hydrofluoroalkane
- Said application does not address the technical problem of the chemical stability of the active ingredient but it rather concerns the drug delivery to lungs.
- WO 00/30608 the applicant has disclosed pressurized MDIs for dispensing a solution of an active ingredient in a hydrofluorocarbon propellant, a co-solvent and optionally a low-volatility component characterized in that part or all of the internal surfaces of said inhalers consist of stainless steel, anodised aluminum or are lined with an inert organic coating.
- the '608 application makes no mention of a critical role of a mineral acid and in particular of phosphoric acid in order to improve the chemical stability of the active ingredient in the composition.
- iprafropium bromide one of the possible active ingredients is stable in particular kinds of cans, with or without acids.
- EP 673240 proposes the use of acids as stabilizers for preventing the chemical degradation of the active ingredient in aerosol solution formulations comprising HFAs.
- Most examples relate to iprafropium bromide, an anticholinergic drug and only an example is presented for a ⁇ 2 -agonist, i.e., fenoterol.
- fenoterol a ⁇ 2 -agonist
- salbutamol is claimed, no exemplary formulations are provided.
- the stability data are reported only for iprafropium bromide and no difference is made between the use of organic and inorganic acids. Phosphoric acid is only cited among the possible inorganic acids.
- WO 98/34596 refers to solution formulations containing a propellant and a physiologically acceptable polymer which could help the solubilization and the stability as well of the active ingredients.
- WO 00/06121 refers to propellant mixtures for aerosol dinitrogen monoxide and a hydrofluoroalkane in the preparation of suspension and solution aerosols.
- Example 7 (1.0 and 1.4 ⁇ l) were reported (Example 7).
- the formulations seemed to be provided with quite good stability if TA 2005 is present in a comparatively high concentration (e.g. 3.5 ⁇ g/50 ⁇ l) and if stored in upright position. Nevertheless, when the present inventors repeated the test with a rather low concentration of TA 2005 (e.g. 1 ⁇ g/63 ⁇ l), they noticed a progressive degradation of the active ingredient in the formulation; see Comparative Examples 1 and 3.
- the formulation exemplified in '689 contained isopropyl myristate as a low volatility compound in order to increase the MMAD (mass median aerodynamic diameter) of the delivered particles.
- TA 2005 it would be highly advantageous to provide highly efficient TA 2005 formulations characterised by a deeper lung penetration by virtue of a significant fraction, of at least 30%, of fine particles, with a diameter equal or less than 1.1 ⁇ m. Therefore the low volatility compound should be avoided. It has been subsequently also found that in this kind of highly efficient: formulations, characterized by the presence of a fraction of particles equal to or less than 1.1 ⁇ m higher than 30% and even than 50% or more, TA 2005 can be present in a very low concentration, starting from 0.0005% w/v based on the total volume of the composition.
- compositions have been described in another previous application of the applicant, WO 03/074025 ('025), wherein stability data of a HFA solution formulation comprising 8-hydroxy-5-[(lR)-l-hydroxy-2-[[(lR)-2-(4-methoxyphenyl)- 1 -methyl ethyl] amino] ethyl] -2(lH)-quinolinone hydrochloride (TA 2005) stabilized by HCl were reported. The stability was determined on a formulation delivering 4 ⁇ g of active compound per actuation, stored upright at 5° C: in said refrigerated conditions, after nine inonths, the TA 2005 assay was higher than 95%; see Comparative Example 2.
- the preferr& mineral acid was hydrochloric acid
- the chemical stability of 8-hydroxy-5-[(lR)-l-hydroxy— 2-[[(lR)-2-(4- methoxyphenyl)-l-methylethyl]amino]ethyl]-2(lH)-quinolinone and its salts is enhanced by small amounts of high concentrated phoshoric acid (i.e.
- the mineral acid that better stabilizes the active ingredient 8-hydr xy-5-[(lR)-l- hydroxy-2-[[(lR)-2-(4-memoxyphenyl)-l-memylethyl]amino]ethyl]-2(lH)-quir ⁇ olinone and its salts in the formulation is phosphoric acid, in particular higher concentrated phosphoric acid.
- the aerosol formulations containing phosphoric acid are surprisingly stable at room temperature for a long life time.
- a method of filling an aerosol inhaler with a composition of the invention comprising: (a) preparing a solution of 8-hydroxy-5-[(lR)-l-hydroxy-2-[[(lR)-2-(4- methoxyphenyl)-l-methylethyl]amino]ethyl]-2(lH)-quinolinone or its salts in one or more co-solvents optionally containing a further active ingredient or excipient or an appropriate amount of a low volatility component; (b) filling the device with said solution; (c) adding a pre-determined amount of a phosphoric acid; (d) adding a propellant containing a hydrofluoroalkane (HFA); and (e) crimping with valves and gassing.
- HFA hydrofluoroalkane
- the active ingredient used in the aerosol compositions of the present invention is a long-acting ⁇ 2 -adrenergic agonist and its combinations with other active ingredients and in particular a corticosteroid or an antimuscarinic drug.
- a corticosteroid are: beclomethasone dipropionate, fluticasone propionate, butixocort, mometasone furoate, triamcinolone acetonide, budesonide and its 22R-epimer, ciclesonide and rofleponide.
- antimuscarinic are iprafropium bromide, oxitropium bromide and tiotropium bromide.
- the active ingredient is 8-hydroxy-5-[(lR)-l-hydroxy-2-[[(lR)-2-(4-methoxy-phenyl)-l- methylethyl]amino]ethyl]-2(lH)-quinolinone or a salt thereof.
- the preferred salt is the hydrochloride salt, sometimes referred to as TA 2005.
- TA 2005 may be prepared as described in U.S. Patent No. RE 33,024. We prefer the formulation to be suitable for delivering a therapeutic amount of the active ingredient in one or two actuations.
- the formulation will be suitable for delivering 0.5-6 ⁇ g/dose, more preferably 1-4 ⁇ g/dose and in particular 1 to 2 ⁇ g/dose or 2 to 3 ⁇ g/dose, either alone or in combination.
- dose we mean the amount of active ingredient delivered by a single actuation of the inhaler.
- the formulations of the present invention will be preferably contained in cans having part or all of the internal surfaces lined with an inert organic coating.
- Examples of preferred coatings are epoxy-phenol resins, perfluoroalkoxyalkane, perfluoroalkoxyalkylene, perfluoroalkylenes such as polytefrafluoroethylene, fluorinated-ethylene-propylene, polyether sulfone and copolymers of fluorinated-ethylene-propylene polyether sulfone.
- Other suitable coatings could be polyamide, polyimide, polyamideimide, polyphenylene sulfide or their combinations.
- the most preferred coatings are perfluoroalkoxyalkane, perfluoroalkoxy-alkylene, perfluoroalkylenes such as polytefrafluoroethylene and fluorinated-ethylene-propylene and copolymers of fluorinated-ethylene-propylene polyether sulfones.
- cans having a rolled-in rim and preferably a part or full rollover rim can be used.
- the formulation is actuated by a metering valve capable of delivering a volume of between 50 ⁇ l and 100 ⁇ l.
- the hydrofluorocarbon propellant is preferably selected from the group of HFA 134a, HFA 227 and mixtures thereof.
- the co-solvent is usually an alcohol, preferably ethanol.
- the apparent pH range is advantageously comprised between 2.5 and 5.5, preferably between 3.0 and 5.5 , even more preferably between 3.5 and 5.0. Rather concentrated, i.e. more than about 10 M, preferably more than about 12 M and most preferably about 15 M phosphoric acid is used to adjust the apparent pH. In the examples that follow 85% i.e.
- 15.2M phosphoric acid has been used.
- the amount of acid to be added to reach the desired apparent pH will be pre- determined in the model vehicle reported before.
- the active ingredient 8-hydroxy-5-[(lR)-l-hydroxy-2-[[(lR)-2-(4-methoxyphenyl)-l- methylethyl]amino]ethyl]-2(lH)-quinolinone or its salt is stabilized with rather concentrated, preferably about 15 M phosphoric acid.
- phosphoric acid in an amount equivalent to 0.0004 to 0.040% w/w of 15M phosphoric acid, based on the total weight of the composition, preferably 0.0008 to 0.020% w/w of 15M phosphoric acid, based on the total weight of the composition, more preferably 0.001 to 0.010% w/w of 15M phosphoric acid, based on the total weight of the composition, still more preferably 0.002 to 0.0075% w/w of 15 M phosphoric acid, based on the total weight of the composition.
- a still high concentrated phosphoric acid other than 15 M can be utilized.
- the person skilled in the art will be able to determine the right percent amount in view of the disclosure in the present application.
- the 8-hydroxy-5-[(lR)-l -hydroxy-2-[[(lR)-2-(4-methoxyphenyl)-l -methylethyl]amino]- ethyl]-2(lH)-quinolinone concentration will vary between 0.0005 % and 0.024 % w/v, based on the total volume of the composition, in order to deliver 0.5-6 ⁇ g per actuation, preferably between 0.001 % and 0.016 % w/v, based on the total volume of the composition, in order to deliver 1 to 4 ⁇ g per actuation, more preferably between 0.001 % and 0.008 % w/v, based on the total volume of the composition, in order to deliver 1 to 2 ⁇ g per actuation.
- the final concentrations of the hydrochloride salt TA 2005 delivered per actuation would be 0.0016 % and 0.0032 % w/v, respectively, based on the total volume of the composition.
- the amount of co-solvent in the composition is suitably 6 to 30 % w/w, preferably 5 to 25 % w/w, more preferably 5 to 20 % w/w, even more preferably 8 to 15 % w/w, based on the total weight of the composition. In these conditions, the stability of TA 2005 is enhanced also at the very low dosage strengths of 0.5 or 1 ⁇ g per actuation.
- the apparent pH values are preferably comprised between 3.0 and 5.0.
- the stabilizing effects of phosphoric acid were also tested in a TA 2005 HFA formulation comprising as a further active ingredient budesonide, an anti-inflammatory 20- ketosteroid which meets with chemical stability problems when formulated in a HFA aerosol solution formulation.
- Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
- EXAMPLES In the following examples and comparative examples, and throughout this specification, all parts and percentages are by weight, and all temperatures are in degrees Celsius, unless expressly stated to be otherwise.
- Comparative Example 1 ( " corresponding to Example 7 of EP 1 157 689) Stability of acidified 8-hydroxy-5-[(lR)-l-hydroxy-2-[[(lR)-2-(4-methoxyphenyl)-l- methylethyl]amino]ethyl]-2(lH)-quinolinone hydrochloride (TA 2005)-HFA 134a solutions in cans coated with a fluorocarbon polymer.
- a formulation of 8-hydroxy-5-[(lR)-l-hydroxy-2-[[(lR)-2-(4-methoxyphenyl)-l- methylethyl]amino]ethyl]-2(lH)-quinolinone hydrochloride (TA 2005) (3.5 ⁇ g/50 ⁇ l) was prepared by dissolving 0.84 mg of the active ingredient in HFA 134a containing 12% w/w ethanol and 1.0% w/w of isopropyl myristate.
- pMDI coated cans containing 1.0 and 1.4 ⁇ l of 0.08 M hydrochloric acid (corresponding respectively to an apparent pH of about 4.8 and 3.2) were set down on storage, upright at 50°C, and samples taken for analysis of TA 2005 contents at appropriate intervals. Stability data obtained are given in Table 1. Each value is expressed as per cent nominal drug concentration. The results indicate that formulations containing from 1.0 to 1.4 ⁇ l of 0.08 M HCl, whose apparent pH is comprised between 3.0 and 5.0, are stable for almost three months at 50° C.
- Comparative Example 2 (corresponding to Example 1 of WO 03/074025) A formulation for delivering a nominal dose of 1 ⁇ g of active ingredient per actuation, was prepared with the following formulation shown in Table 2. Table 2:
- Comparative Example 3 Two aluminum canisters having the internal surface coated with teflon and fitted with commercial valves having a 63 ⁇ l metering chamber were filled with the following formulations shown in Table 3.
- TA 2005 (8-hydroxy-5- [(lR)-l-hydroxy-2-[[(lR)-2-(4-methoxyphenyl)-l-methylethyl]amino]ethyl]-2(lH)- quinolinone hydrochloride) can be stabilized by the use of hydrochloric acid if TA 2005 is present in the solution formulation in a comparatively high concentration (3.5 ⁇ g/50 ⁇ l; 4 ⁇ g /63 ⁇ l, respectively) and in refrigerated conditions.
- the active ingredient 8-hydroxy-5-[(lR)- 1 -hydroxy-2- [ [( 1 R)-2-(4-methoxyphenyl)- 1 -methylethyl] amino] ethyl] -2(1 H)-quinolinone hydrochloride is a very potent long acting ⁇ 2 -agonist active at a very low dosage-strength, which should be applied in a low concentration. Moreover, the storage in a refrigerator should be avoided.
- 8-hydroxy-5- [(lR)-l-hydroxy-2-[[(lR)-2-(4-methoxyphenyl)-l-methylethyl]amino]ethyl]-2(lH)- quinolinone hydrochloride can, however, be stabilized also in very low concentrations (e.g.
- Example 1 by the use of phosphoric acid in an amount equivalent to 0.0004 to 0.040 % w/w, preferably 0.0008 to 0.020 % w/w, more preferably 0.001 to 0.010 % w/w, still more preferably 0.002 to 0.0075% w/w of 15.2 M phosphoric acid, based on the total weight of the composition.
- Example 1 Example 1 :
- formulations capable of delivering a nominal dose of 0.5, 1.5, 2, 2.5, 3, 3.5 or 4 ⁇ g of active ingredient per actuation may also be prepared.
- Table 4 120 actuations/canister, overage of 30 actuations
- aluminum canisters having the internal surface coated with teflon and fitted with commercial valves having a 63 ⁇ l metering chamber.
- a stability study was carried out by storing the formulation in upright and inverted cans at 40° C and 75% relative humidity. After six months of storage under these conditions the percent recovery of the active ingredient was very good with residual percent amount of TA 2005 up to 98% in the range of phosphoric acid of 0.001 to 0.0027% w/w.
- Example 2 Two compositions were tested containing TA 2005 and budesonide as active ingredients and two different concentrations of phosphoric acid.
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007500175A JP2007523942A (en) | 2004-02-27 | 2005-02-25 | Stable drug solution formulation for pressurized metered dose inhalers |
NZ549138A NZ549138A (en) | 2004-02-27 | 2005-02-25 | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
AU2005218750A AU2005218750A1 (en) | 2004-02-27 | 2005-02-25 | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
EP05707641A EP1715849A1 (en) | 2004-02-27 | 2005-02-25 | Stable pharmaceutical solution formulation for pressurized metered dose inhalers |
EA200601578A EA010311B1 (en) | 2004-02-27 | 2005-02-25 | Aerosol solution formulations, pressurized metered dose inhalers and method for filling thereof |
BRPI0507225A BRPI0507225A2 (en) | 2004-02-27 | 2005-02-25 | stable pharmaceutical solution formulations for pressurized metered dose inhalers |
CA002557435A CA2557435A1 (en) | 2004-02-27 | 2005-02-25 | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
IL177103A IL177103A0 (en) | 2004-02-27 | 2006-07-26 | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
TNP2006000250A TNSN06250A1 (en) | 2004-05-13 | 2006-08-04 | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
US11/467,515 US20070025920A1 (en) | 2004-02-27 | 2006-08-25 | Stable Pharmaceutical Solution Formulations for Pressurized Metered Dose Inhalers |
NO20064359A NO20064359L (en) | 2004-02-27 | 2006-09-26 | Stable pharmaceutical solution formulation for pressurized dosage inhaler |
HK07107282.5A HK1103280A1 (en) | 2004-02-27 | 2007-07-06 | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54779804P | 2004-02-27 | 2004-02-27 | |
US60/547,798 | 2004-02-27 | ||
EP04011424.1 | 2004-05-13 | ||
EP04011424A EP1595531A1 (en) | 2004-05-13 | 2004-05-13 | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/467,515 Continuation US20070025920A1 (en) | 2004-02-27 | 2006-08-25 | Stable Pharmaceutical Solution Formulations for Pressurized Metered Dose Inhalers |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005084640A1 true WO2005084640A1 (en) | 2005-09-15 |
Family
ID=34924994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/002042 WO2005084640A1 (en) | 2004-02-27 | 2005-02-25 | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
Country Status (12)
Country | Link |
---|---|
US (1) | US7381402B2 (en) |
EP (2) | EP1595531A1 (en) |
JP (1) | JP2007523942A (en) |
AU (1) | AU2005218750A1 (en) |
BR (1) | BRPI0507225A2 (en) |
CA (1) | CA2557435A1 (en) |
EA (1) | EA010311B1 (en) |
MY (1) | MY143075A (en) |
NZ (1) | NZ549138A (en) |
SG (1) | SG150558A1 (en) |
TN (1) | TNSN06250A1 (en) |
WO (1) | WO2005084640A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005112902A2 (en) * | 2004-05-13 | 2005-12-01 | Chiesi Farmaceutici S.P.A. | Medicinal aerosol formulation products with improved chemical stability |
AU2007241336B2 (en) * | 2006-04-21 | 2012-12-06 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
US8877164B2 (en) | 2005-02-25 | 2014-11-04 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ2947A1 (en) * | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Pressure metered dose inhaler. |
US6315985B1 (en) * | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
JP5392880B2 (en) * | 2000-05-22 | 2014-01-22 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Stable pharmaceutical solution formulation for pressurized metered dose inhalers |
EP1415647A1 (en) * | 2002-10-23 | 2004-05-06 | CHIESI FARMACEUTICI S.p.A. | "Long-acting beta-2 agonists ultrafine formulations" |
EP3536344B1 (en) * | 2002-03-01 | 2020-02-19 | Chiesi Farmaceutici S.p.A. | Formoterol superfine formulation |
EP1340492A1 (en) * | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Aerosol formulations for pulmonary administration of medicaments having systemic effects |
EP1452179A1 (en) * | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
EP1595531A1 (en) | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
KR20070000476A (en) * | 2004-02-27 | 2007-01-02 | 키에시 파르마슈티시 엣스. 피. 에이. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
US8227027B2 (en) | 2007-12-07 | 2012-07-24 | Presspart Gmbh & Co. Kg | Method for applying a polymer coating to an internal surface of a container |
MX2012005711A (en) * | 2009-11-17 | 2012-10-05 | Cipla Ltd | Inhalation solutions. |
MX2012008906A (en) * | 2010-02-10 | 2012-08-15 | Astrazeneca Uk Ltd | Process for providing a filled canister for an inhaler. |
AU2014375300B2 (en) * | 2013-12-30 | 2019-10-24 | Chiesi Farmaceutici S.P.A. | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994013263A1 (en) * | 1992-12-09 | 1994-06-23 | Jager Paul D | Stabilized medicinal aerosol solution formulations |
WO2000030608A1 (en) * | 1998-11-25 | 2000-06-02 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers (mdi) |
US6150418A (en) * | 1998-10-17 | 2000-11-21 | Boehringer Ingelheim Pharma Kg | Active substance concentrate with formoterol, suitable for storage |
EP1157689A1 (en) * | 2000-05-22 | 2001-11-28 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
WO2003074025A2 (en) * | 2002-03-01 | 2003-09-12 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers containing solutions of beta-2 agonists |
EP1415647A1 (en) * | 2002-10-23 | 2004-05-06 | CHIESI FARMACEUTICI S.p.A. | "Long-acting beta-2 agonists ultrafine formulations" |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3361306A (en) | 1966-03-31 | 1968-01-02 | Merck & Co Inc | Aerosol unit dispensing uniform amounts of a medically active ingredient |
US3622053A (en) | 1969-12-10 | 1971-11-23 | Schering Corp | Aerosol inhaler with flip-up nozzle |
MX3864E (en) | 1975-05-27 | 1981-08-26 | Syntex Corp | A PROCESS TO PREPARE THE CRYSTALLINE COMPOUND 6-FLUIRO-11B 21-DIHIROXI-16 17-ISOPROPILIDENDIOXIPREGNA-1 4-DIEN-3 20-DIONA |
US4185100A (en) | 1976-05-13 | 1980-01-22 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
US4499108A (en) | 1983-06-08 | 1985-02-12 | Schering Corporation | Stable pleasant-tasting albuterol sulfate pharmaceutical formulations |
GB8334494D0 (en) * | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
IT1196142B (en) | 1984-06-11 | 1988-11-10 | Sicor Spa | PROCEDURE FOR THE PREPARATION OF 16.17-ACETALS OF PREGNANIC DERIVATIVES AND NEW COMPOUNDS OBTAINED |
US4584320A (en) | 1985-01-03 | 1986-04-22 | David Rubin | Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid |
US5192528A (en) | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
IL97065A (en) | 1990-02-02 | 1994-01-25 | Fisons Plc | Aerosol propellant compositions |
WO1992011236A1 (en) | 1990-12-19 | 1992-07-09 | Smithkline Beecham Corporation | Aerosol formulations |
US6006745A (en) | 1990-12-21 | 1999-12-28 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
EP0504112A3 (en) | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
RU2114642C1 (en) | 1991-05-21 | 1998-07-10 | Эбботт Лабораториз | Aerosol inhalation device |
AU653634B2 (en) | 1991-08-29 | 1994-10-06 | Broncho-Air Medizintechnik Ag | Medical appliance for inhaling metered aerosols |
IL103238A (en) | 1991-09-25 | 1995-07-31 | Fisons Plc | Pressurised aerosol compositions |
IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
ES2216800T3 (en) | 1991-12-18 | 2004-11-01 | Minnesota Mining And Manufacturing Company | AEROSOL FORMULATIONS IN SUSPENSION. |
DE4230876A1 (en) | 1992-03-17 | 1993-09-23 | Asta Medica Ag | COMPRESSED GAS PACKS USING POLYOXYETHYLENE GLYCERYL OLEATES |
SE9203743D0 (en) | 1992-12-11 | 1992-12-11 | Astra Ab | EFFICIENT USE |
AU4066693A (en) | 1992-12-23 | 1994-07-19 | Bernhard Hugemann | Compacted drug body for use in the mechanical generation of inhalable active-substance particles |
US6042811A (en) | 1993-03-17 | 2000-03-28 | 3M Innovative Properties Company | Aerosol formulation containing a diol-diacid derived dispersing aid |
DE69413955T2 (en) | 1993-03-17 | 1999-04-01 | Minnesota Mining & Mfg | AEROSOL COMPOSITION CONTAINING A DERIVATIVE DERIVATIVE FROM ESTER, AMID OR MERCAPTOESTER |
US6596260B1 (en) | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
CA2178473C (en) | 1993-12-20 | 2004-08-24 | Tsi-Zong Tzou | Flunisolide aerosol formulations |
GB9425160D0 (en) | 1994-12-10 | 1995-02-08 | Glaxo Group Ltd | Medicaments |
PL320856A1 (en) | 1994-12-22 | 1997-11-10 | Astra Ab | Aerosol drug preparations |
GB9426252D0 (en) | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
DE4446891A1 (en) | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stable aqueous budesonide solution |
US5653961A (en) | 1995-03-31 | 1997-08-05 | Minnesota Mining And Manufacturing Company | Butixocort aerosol formulations in hydrofluorocarbon propellant |
SK284448B6 (en) * | 1995-04-14 | 2005-04-01 | Glaxo Wellcome Inc. | Metered dose inhaler |
SK284447B6 (en) | 1995-04-14 | 2005-04-01 | Glaxo Wellcome Inc. | Metered dose inhaler |
ES2179192T3 (en) | 1995-04-14 | 2003-01-16 | Smithkline Beecham Corp | DOSING INHIBITOR FOR ALBUTEROL. |
CA2218179A1 (en) | 1995-04-14 | 1996-10-17 | Glaxo Wellcome Inc. | Metered dose inhaler for beclomethasone dipropionate |
GB9612297D0 (en) | 1996-06-11 | 1996-08-14 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
EP0914143A1 (en) | 1996-07-08 | 1999-05-12 | Rhone-Poulenc Rorer Limited | Medicinal cyclosporin-a aerosol solution formulation |
WO1998003533A1 (en) | 1996-07-24 | 1998-01-29 | Oligos Etc. And Oligos Therapeutics, Inc. | Antisense oligonucleotides as antibacterial agents |
GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
GB9620187D0 (en) | 1996-09-27 | 1996-11-13 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
WO1998024420A1 (en) | 1996-12-04 | 1998-06-11 | Bioglan Ireland (R & D) Limited | Pharmaceutical compositions and devices for their administration |
US6413496B1 (en) | 1996-12-04 | 2002-07-02 | Biogland Ireland (R&D) Limited | Pharmaceutical compositions and devices for their administration |
CA2280099C (en) | 1997-02-05 | 2005-12-27 | Jago Pharma Ag | Medical aerosol formulations |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
US5891419A (en) | 1997-04-21 | 1999-04-06 | Aeropharm Technology Limited | Environmentally safe flunisolide aerosol formulations for oral inhalation |
US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
GB2326334A (en) | 1997-06-13 | 1998-12-23 | Chiesi Farma Spa | Pharmaceutical aerosol compositions |
BR7702049U (en) | 1997-09-05 | 1999-09-14 | Chiesi Farma Spa | Spray nozzle for use in an oral inhaler for aerosol medicines |
NZ504021A (en) | 1997-10-17 | 2003-04-29 | Systemic Pulmonary Delivery Lt | Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication |
US6045784A (en) | 1998-05-07 | 2000-04-04 | The Procter & Gamble Company | Aerosol package compositions containing fluorinated hydrocarbon propellants |
SE9802073D0 (en) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
IL140353A0 (en) | 1998-06-18 | 2002-02-10 | Boehringer Ingelheim Pharma | Pharmaceutical formulations for aerosols with two or more active substances |
US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
US6241969B1 (en) | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
CN1158996C (en) | 1998-07-24 | 2004-07-28 | 杰格研究股份公司 | Medicinal aerosol for mulations |
PT1102579E (en) | 1998-08-04 | 2003-07-31 | Jago Res Ag | MEDICINAL AEROSOL FORMULATIONS |
SI1121112T1 (en) | 1998-10-17 | 2002-10-31 | Boehringer Ingelheim Pharma Kg | Stable formoterol concentrate |
DK1283036T3 (en) | 1998-11-13 | 2008-03-25 | Jagotec Ag | Dry powder for inhalation |
IT1303788B1 (en) | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | MEDICINAL AEROSOL FORMULATIONS. |
US6290930B1 (en) | 1998-12-18 | 2001-09-18 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide |
US6004537A (en) | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
US6315985B1 (en) | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
IT1317846B1 (en) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | FORMULATIONS CONTAINING AN ANTICOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCOPNEUMOPATHY. |
IT1318514B1 (en) | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | FORMULATIONS CONTAINING A GLUCOCORTICOSTEROID DRUG FOR THE TREATMENT OF BRONCOPOLMONARY DISEASES. |
EP1340492A1 (en) * | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Aerosol formulations for pulmonary administration of medicaments having systemic effects |
EP1595531A1 (en) | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
-
2004
- 2004-05-13 EP EP04011424A patent/EP1595531A1/en not_active Withdrawn
-
2005
- 2005-02-22 MY MYPI20050670A patent/MY143075A/en unknown
- 2005-02-25 JP JP2007500175A patent/JP2007523942A/en active Pending
- 2005-02-25 EP EP05707641A patent/EP1715849A1/en not_active Withdrawn
- 2005-02-25 BR BRPI0507225A patent/BRPI0507225A2/en not_active IP Right Cessation
- 2005-02-25 EA EA200601578A patent/EA010311B1/en not_active IP Right Cessation
- 2005-02-25 US US11/065,569 patent/US7381402B2/en not_active Expired - Fee Related
- 2005-02-25 CA CA002557435A patent/CA2557435A1/en not_active Abandoned
- 2005-02-25 WO PCT/EP2005/002042 patent/WO2005084640A1/en active Application Filing
- 2005-02-25 NZ NZ549138A patent/NZ549138A/en unknown
- 2005-02-25 SG SG200901439-0A patent/SG150558A1/en unknown
- 2005-02-25 AU AU2005218750A patent/AU2005218750A1/en not_active Abandoned
-
2006
- 2006-08-04 TN TNP2006000250A patent/TNSN06250A1/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994013263A1 (en) * | 1992-12-09 | 1994-06-23 | Jager Paul D | Stabilized medicinal aerosol solution formulations |
US6150418A (en) * | 1998-10-17 | 2000-11-21 | Boehringer Ingelheim Pharma Kg | Active substance concentrate with formoterol, suitable for storage |
WO2000030608A1 (en) * | 1998-11-25 | 2000-06-02 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers (mdi) |
US20030089369A1 (en) * | 1998-11-25 | 2003-05-15 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers (MDI) |
EP1157689A1 (en) * | 2000-05-22 | 2001-11-28 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
WO2003074025A2 (en) * | 2002-03-01 | 2003-09-12 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers containing solutions of beta-2 agonists |
EP1415647A1 (en) * | 2002-10-23 | 2004-05-06 | CHIESI FARMACEUTICI S.p.A. | "Long-acting beta-2 agonists ultrafine formulations" |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005112902A2 (en) * | 2004-05-13 | 2005-12-01 | Chiesi Farmaceutici S.P.A. | Medicinal aerosol formulation products with improved chemical stability |
WO2005112902A3 (en) * | 2004-05-13 | 2006-05-04 | Chiesi Farma Spa | Medicinal aerosol formulation products with improved chemical stability |
US8877164B2 (en) | 2005-02-25 | 2014-11-04 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent |
EP1850831B1 (en) * | 2005-02-25 | 2015-12-02 | CHIESI FARMACEUTICI S.p.A. | Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent |
AU2007241336B2 (en) * | 2006-04-21 | 2012-12-06 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
AU2007241336C1 (en) * | 2006-04-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
Also Published As
Publication number | Publication date |
---|---|
SG150558A1 (en) | 2009-03-30 |
BRPI0507225A2 (en) | 2017-05-30 |
MY143075A (en) | 2011-02-28 |
JP2007523942A (en) | 2007-08-23 |
EA010311B1 (en) | 2008-08-29 |
CA2557435A1 (en) | 2005-09-15 |
EA200601578A1 (en) | 2007-02-27 |
NZ549138A (en) | 2009-08-28 |
TNSN06250A1 (en) | 2007-12-03 |
US20050220718A1 (en) | 2005-10-06 |
AU2005218750A1 (en) | 2005-09-15 |
EP1715849A1 (en) | 2006-11-02 |
EP1595531A1 (en) | 2005-11-16 |
US7381402B2 (en) | 2008-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7381402B2 (en) | Stable pharmaceutical solution formulations for pressurized metered dose inhalers | |
EP2223682B1 (en) | Stable pharmaceutical solution formulations for pressurised metered dose inhalers | |
US20060257324A1 (en) | Pharmaceutical solution formulations for pressurised metered dose inhalers | |
JP2023546025A (en) | Pharmaceutical formulations for pressurized metered dose inhalers | |
EP2482799B1 (en) | Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate | |
AU2005293328A1 (en) | Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister | |
US20070025920A1 (en) | Stable Pharmaceutical Solution Formulations for Pressurized Metered Dose Inhalers | |
KR20060136446A (en) | Stable pharmaceutical solution formulations for pressurized metered dose inhalers | |
MXPA06009584A (en) | Stable pharmaceutical solution formulations for pressurized metered dose inhalers | |
JP5409594B2 (en) | Stable pharmaceutical solution formulation for pressurized metered dose inhalers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 177103 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006501486 Country of ref document: PH Ref document number: 2005707641 Country of ref document: EP Ref document number: 2173/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200606577 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067015964 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005218750 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 549138 Country of ref document: NZ Ref document number: 06079926 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/009584 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2557435 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580006060.3 Country of ref document: CN Ref document number: 11467515 Country of ref document: US Ref document number: 2007500175 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2005218750 Country of ref document: AU Date of ref document: 20050225 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005218750 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200601517 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 9632 Country of ref document: GE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200601578 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 2005707641 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067015964 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 11467515 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI0507225 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI0507225 Country of ref document: BR Kind code of ref document: A2 Effective date: 20060825 |